Scott K. Reed

Representative Matters

• Alkermes in Luye Pharma v. Alkermes and Alkermes and Janssen v. Luye Pharma (injectable suspensions, including a long-acting injection of risperidone used to treat schizophrenia)
• Allergan in Allergan v. Aurobindo, Allergan v. Wilshire and Allergan v. Sometset (ophthalmic formulations of alcaftadine for once-daily treatment of allergic conjunctivitis)
• Alnylam in Alnylam v. Silence Therapeutics (RNA interference (RNAi) therapeutic platform technology)
• Astellas in Astellas v. Actavis, Sandoz, Sawai, Lupin, Zydus, Prinston, Aurobindo, Apotex and Windlas (polymorphism and compounds to treat overactive bladder)
• Bausch Health in Bausch & Lomb v. Alcon and Bausch & Lomb v. Allergan (contact lens care products containing proteolytic enzymes and antimicrobial agents); Visx v. Bausch & Lomb (laser eye surgery); Allergan v. Bausch & Lomb (intraocular lenses); Allergan v. Bausch & Lomb (anti-glaucoma pharmaceuticals); Bausch & Lomb v. GNC, Bausch & Lomb v. Leiner, Bausch & Lomb v. Alcon, Bausch & Lomb v. Rexall, and Bausch & Lomb v. Vitamin Health (nutritional supplement to treat macular degeneration); Valeant v. Actavis (polymorphism and compounds to treat Irritable Bowel Syndrome with Diarrhea and Hepatic Encephalopathy); Bausch Health v. Sun (polymorphism and compounds to treat Travelers Diarrhea)); Bausch Health v. Sandoz (polymorphism and compounds to treat Irritable Bowel Syndrome with Diarrhea)
• Bristol-Myers Squibb in Regents of the University of Michigan and Repligen Corporation v. Bristol-Myers Squibb (fusion protein regulation of the immune system); Housey Pharmaceuticals v. Bristol-Myers Squibb (cell-based biotechnology assays); Zymogenetics v. Bristol-Myers Squibb (fusion proteins); and Regents of the University of Michigan and Repligen Corporation v. Bristol-Myers (rheumatoid arthritis pharmaceuticals)
• Canon in Intellectual Ventures v. Canon (graphical user interface and image sensor technology); Honeywell v. Canon (autofocus camera technology); and Gross v. Canon (microprocessor technology and optical devices)
• DuPont in Schneider v. DuPont and DuPont v. Cordis (polymeric balloon angioplasty materials)
• Emory University in Emory University v. Glaxo Wellcome (anti-hepatitis pharmaceuticals) and Emory University v. Glaxo Wellcome and BioChem Pharma (anti-AIDS pharmaceuticals)
• Genzyme in Bonecare and Genzyme v. Pentech, Eagle, Sandoz, Anchen, and Roxane (kidney disease pharmaceuticals); Bonecare and Genzyme v. Impax, Lupin, Endo, Teva, Watson, and Sandoz (kidney disease pharmaceuticals); Daiichi Sankyo and Genzyme v. Impax and Lupin (anti-cholesterol pharmaceuticals)
• GlaxoSmithKline in GlaxoSmithKline v. Barr (prostate pharmaceuticals) and Pozen v. Par (migraine pharmaceuticals)
• IBM in Berkeley v. IBM (personal computers) and Valutron v. IBM (point-of-sale devices)
• Mitsui in 3M v. Mitsui (adhesive technology)
• Novartis in Novartis v. Abbott (organ transplant cyclosporin pharmaceuticals)
• Pfizer in Pfizer v. Barr (estrogen contraceptive pharmaceuticals) and Pfizer v. Barr (hormone replacement therapy pharmaceuticals)
• Quebec Metal Powders in Hoeganaes v. Quebec Metal Powders (powder metallurgy)
• Regeneron in Regeneron v. Genentech (macular degeneration pharmaceuticals) and Regeneron v. Merus (transgenic mice) 
• Sanofi-Aventis in Sanofi v. Genentech (anti-cancer pharmaceuticals) and Sanofi v. Genentech (macular degeneration pharmaceuticals)
• UCB in UCB v. Mylan, UCB v. Dr. Reddy’s, UCB v. Ivax, UCB v. Sandoz, and UCB v. Cobalt (epilepsy pharmaceuticals); UCB and Research Corporation Technologies v. Glemnmark (epilepsy pharmaceuticals) UCB v. KV, UCB v. Mallinckrodt, and UCB v. Teva (attention deficit disorder pharmaceuticals)
• Union Carbide in BP v. Union Carbide (polyethylene processing technology)

Representative Clients

• Alfasigma S.p.A
• Alkermes
• Allergan
• Alnylam
• Astellas Pharma
• Bausch Health
• Canon
• Emory University
• Gates Foundation
• Genzyme
• Regeneron
• Sanofi

Education

• J.D. University of New Hampshire, Franklin Pierce Law Center 1987
• • Editorial Board (IDEA) Journal of Law and Technology
• B.S. Chemistry and Economics Ursinus College 1984

Bar Admissions

• New York
• U.S. Patent and Trademark Office

Court Admissions

• U.S. Court of Appeals for the Federal Circuit
• U.S. District Court for the Southern District of New York
• U.S. District Court for the Eastern District of New York
• U.S. District Court for the Western District of New York

Scott is known as a “consummate trial lawyer who discerns how to persuade the judge and jurors” and who produces “consistently excellent results” (IAM Patent 1000, 2012). He is a “versatile operator with extensive first-chair experience” (IAM Patent 1000, 2013) and brings “a lot of sage advice and experience” (Legal 500, 2012) as well as “his enthusiasm to cases, leading a professional team” (Legal 500, 2008).

• Who's Who Legal, Life Sciences – Patent Litigation, 2021
• The Best Lawyers in America, Litigation – Patent, 2016 – 2024
• Corporate INTL Magazine, Global Award: IP Litigation Attorney of the Year, New York, 2017
• Managing Intellectual Property, IP Star, 2014 – 2020, 2022 – 2023
• IAM Patent 1000, The World’s Leading Patent Professionals, 2012 – 2019, 2022 – 2023
• PLC Which Lawyer, IP: Patent Litigation, 2012
• IAM 250, The World’s Leading Patent Litigators, 2011
• Legal 500, Patent Litigation: Full Coverage, 2007 – 2010, 2012 – 2013, 2019 – 2021, 2023
• Legal Media Group, The World’s Leading Patent Law Practitioners, 2007 – 2010
• LMG Life Sciences, 2012 – 2020
• Leaders League
  • Leading Attorney, Patent Litigation, New York, 2012, 2014 – 2015
  • Leading Attorney, Patent Litigation, Nationwide, 2014 – 2015
• Super Lawyers, Top Litigator, Intellectual Property, New York Metro, 2013 – 2023